Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Breast Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
48 drugs · 217 active trials
17 drugs · 330 active trials
43 drugs · 1,254 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 9 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Brigatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 7, 2020 |
| Icotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2015-01 |
| Ixazomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 21, 2016 |
| Linifanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-07 |
| Linsitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-08 |
| MEK Inhibitor CI-1040 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2002-02 |
| Mercaptopurine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-05 |
| Mirdametinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 14, 2021 |
| Nimotuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-09 |
| Onartuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-03 |
| Pasireotide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-09 |
| Patritumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-11 |
| PD1 Inhibitor | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 19, 2021 |
| Peginterferon Alfa-2a | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-09 |
| Pemrametostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 8, 2021 |
| Pixantrone Dimaleate | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-05 |
| Pralatrexate | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-03 |
| Pralsetinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 7, 2020 |
| Repotrectinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 8, 2024 |
| Selective Estrogen Receptor Covalent Antagonist H3B-6545 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 23, 2017 |
| Selpercatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 7, 2020 |
| Taletrectinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2026-10 |
| Tegafur | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2000-02 |
| Tepotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 7, 2020 |
| Triciribine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-01 |
| Tyrosine Kinase Inhibitor | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 1, 2021 |
| Uprosertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 2, 2013 |
| Verteporfin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2016-10 |
| Daratumumab | Phase 1 | Phase 1 | 1 | 1 | 0 | 2 | 0 | — | — | Mar 27, 2018 |
| FOLFOX Regimen | Phase 1 | Phase 1 | 1 | 1 | 0 | 2 | 0 | — | — | Nov 15, 2013 |
| Berzosertib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Sep 24, 2020 |
| Elimusertib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 25, 2021 |
| Lenalidomide | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Jul 30, 2026 |
| Pidnarulex | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Oct 5, 2026 |
| Belinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | Mar 27, 2018 |
| Onalespib | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | Nov 19, 2010 |
| Samotolisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | Jul 31, 2012 |
| Abiraterone | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Apr 1, 2020 |
| Birabresib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Oct 23, 2014 |
| Dinaciclib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Aug 21, 2012 |
| Sonidegib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2012-07 |
| 2-Deoxy-D-glucose | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-02 |
| Abexinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 31, 2021 |
| Alitretinoin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 1996-05 |
| Aurora A Kinase Inhibitor LY3295668 Erbumine | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 2, 2019 |
| Axitinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 11, 2023 |
| Brentuximab Vedotin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 29, 2020 |
| Carfilzomib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 27, 2018 |
| Dacarbazine | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 14, 2007 |
| Enasidenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.